B of A Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80

Benzinga Newsdesk www.benzinga.com Neutral 54.3%

Neg 0% Neu 54.3% Pos 0%

B of A Securities analyst Jason Zemansky maintains BioMarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $85 to $80.